Phase II Study of Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Washington University School of Medicine
Summary
Advanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: Patients eligible for definitive chemoradiotherapy, including brachytherapy * Patient age ≥ 18 years. * Patients with histologically confirmed newly diagnosed advanced cervical cancer (squamous, adenosquamous, adenocarcinoma or poorly differentiated); Federation of Gynecology and Obstetrics (FIGO) 2018 clinical stages III-IVA. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Absolute neutrophil count ≥ 1,500/mcL. * Platelets ≥ 100,000/mcL. * Hemoglobin ≥ 8 g/dL (can be transfused prior to study). * Total bilirubin ≤ 1.5 x institutional upper limit of n…
Interventions
- DrugTelaglenastat
-800 mg twice per day by mouth
- RadiationRadiation treatment
* Standard of care * External beam radiation therapy delivered daily 4 days a week and 1 day per week of brachytherapy.
- DrugCisplatin
* Standard of care * Weekly administration of cisplain
Location
- Washington University School of MedicineSt Louis, Missouri